Jiang Xiaolei, Zhuang Yafeng, Meng Tiancheng, Meng Tianwei, Li Xinghua, He Dan, Meng Hongyu, Chang Hong
Department of Nephrology and Endocrinology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
College of Pharmacy, Baotou Medical College, Baotou, China.
Front Microbiol. 2025 Sep 1;16:1570229. doi: 10.3389/fmicb.2025.1570229. eCollection 2025.
Liver injury (LI) is responsible for a significant number of fatalities each year. In the context of Mongolian medicine, (Blume) G. Don (RM) is utilized for its properties to treatment of hepatic disorders. However, the underlying mechanisms of its action remain poorly understood.
Clarifying the process through which RM enhances LI.
The chemical constituents were subjected to analysis, and network pharmacology alongside molecular docking studies were conducted. Additionally, ELISA, staining techniques, metabolomic analyses, and 16S rDNA sequencing were performed.
A total of 17 components have been identified from RM, including liver disease-related compounds such as kaempferol, emodin, quercetin. Network pharmacology has identified notable genes that exhibit a strong binding affinity to active compounds, including emodin, which interacts with IL6 and PPARG, and aloeemodin, which binds to IL6 and AKT1. In a rat model of LI induced by CCL, low dose (0.07875 g/kg) of RM demonstrated a reduction in ALT and γ-GT levels ( < 0.05). Metabolomic analysis indicated that RM has an impact on the concentrations of 13-OxoODE, morphine, and niacinamide in rat models exhibiting LI, simultaneously several metabolic pathways, including steroid biosynthesis, linoleic acid metabolism, and tryptophan metabolism. By integrating the findings from metabolomics with KEGG pathways, it was determined that RM may ameliorate LI by activating specific pathways and modulating fatty acid metabolic processes, particularly linoleic acid and arachidonic acid metabolism. Furthermore, low-dose RM (RML) was found to enhance beneficial gut microbiota such as , suggesting its potential role in the regulation of intestinal homeostasis and barrier integrity.
RML has the potential to enhance the composition of intestinal microbiota by through the differential regulation of various metabolized components, including 13-OxoODE, morphine, and niacinamide, it influences several metabolic pathways, notably steroid biosynthesis, lysine degradation, interconversions of pentose and glucuronate, as well as the metabolism of linoleic acid. Additionally, it may promote the proliferation of and probiotics, thereby contributing to the amelioration of LI. It establishes a robust foundation for future applications and the development of associated pharmaceuticals.
肝损伤(LI)每年导致大量死亡。在蒙医学中,(Blume)G. Don(RM)因其治疗肝脏疾病的特性而被使用。然而,其作用的潜在机制仍知之甚少。
阐明RM改善LI的过程。
对化学成分进行分析,并进行网络药理学和分子对接研究。此外,还进行了ELISA、染色技术、代谢组学分析和16S rDNA测序。
从RM中总共鉴定出17种成分,包括与肝病相关的化合物,如槲皮素、大黄素、槲皮素。网络药理学已鉴定出与活性化合物具有强结合亲和力的显著基因,包括与IL6和PPARG相互作用的大黄素,以及与IL6和AKT1结合的芦荟大黄素。在CCL诱导的LI大鼠模型中,低剂量(0.07875 g/kg)的RM显示ALT和γ-GT水平降低(<0.05)。代谢组学分析表明,RM对LI大鼠模型中13-氧代十八碳二烯酸(13-OxoODE)、吗啡和烟酰胺的浓度有影响,同时还影响几种代谢途径,包括类固醇生物合成、亚油酸代谢和色氨酸代谢。通过将代谢组学的研究结果与KEGG途径相结合,确定RM可能通过激活特定途径和调节脂肪酸代谢过程,特别是亚油酸和花生四烯酸代谢来改善LI。此外,发现低剂量RM(RML)可增强有益的肠道微生物群,如,表明其在调节肠道稳态和屏障完整性方面的潜在作用。
RML有可能通过对包括13-OxoODE、吗啡和烟酰胺在内的各种代谢成分的差异调节来改善肠道微生物群的组成,它影响几种代谢途径,特别是类固醇生物合成、赖氨酸降解、戊糖和葡萄糖醛酸的相互转化以及亚油酸的代谢。此外,它可能促进和益生菌的增殖,从而有助于改善LI。它为未来的应用和相关药物的开发奠定了坚实的基础。